Did your Medtronic MiniMed insulin pump fail — and did your doctor miss the warning signs?
Key fact: Medtronic issued multiple recalls and hazard alerts for MiniMed insulin pump models between 2019 and 2023, including alerts recognised by the Therapeutic Goods Administration (TGA) in Australia.
Key fact: Known failure modes include unintended insulin delivery, occlusion alarms that fail to trigger, and cybersecurity vulnerabilities allowing unauthorised dose changes.
Key fact: Clinicians who prescribe or manage insulin pump therapy carry a duty to monitor for device safety alerts and to inform patients when a recall applies to their device.
Key fact: Harm from a pump failure can escalate within hours. Delayed clinical response is one of the most common failure patterns in these cases.
Understanding the Medtronic MiniMed insulin pump: what normally happens
An insulin pump is a small, computerised device worn on the body. It delivers insulin continuously through a thin tube inserted under the skin. Doctors prescribe pumps to people with Type 1 diabetes — and sometimes Type 2 — when injections alone cannot keep blood sugar stable enough.
The Medtronic MiniMed range is one of the most widely prescribed pump systems in Australia. Models such as the MiniMed 630G, 670G, and 770G include automated features that adjust insulin delivery based on continuous glucose readings. Patients and their families often rely on these devices completely, trusting that the technology will perform as designed.
Proper care around insulin pump therapy involves more than simply prescribing the device. The prescribing clinician — usually an endocrinologist or diabetes specialist — must explain how the pump works, what alarms mean, and what to do if the device behaves unexpectedly. Regular follow-up appointments allow the clinical team to check that the pump is delivering correctly and that the patient’s glucose levels remain in a safe range.
For more general information about diabetes management and insulin therapy, Healthdirect Australia provides plain-English resources written for patients.
When things start to go wrong
Pump failures do not always announce themselves clearly. Some malfunctions produce obvious alarms. Others are silent — the pump appears to be working while delivering too much or too little insulin. Patients and carers often notice something is wrong before any alarm sounds.
Warning signs that should have prompted urgent clinical action:
• Unexplained high blood sugar (hyperglycaemia) that does not respond to correction doses
• Unexplained low blood sugar (hypoglycaemia) with no obvious dietary cause
• Pump alarms that activate repeatedly without a clear reason
• Insulin reservoir appearing to empty faster or slower than expected
• Infusion site problems — redness, swelling, or insulin leaking at the insertion point
• The patient reporting that the pump “feels different” or is behaving unusually
• A known TGA or manufacturer recall applying to the patient’s specific pump model or serial number
Each of these signs, on its own, might have an innocent explanation. But a clinician who dismisses repeated reports of unexplained glucose swings — without checking whether a safety alert applies to that patient’s device — may have fallen below the standard of care.
A common pattern — where care can break down
Failures in MiniMed pump cases rarely happen in one dramatic moment. More often, a series of smaller oversights compounds into serious harm. The Australian Commission on Safety and Quality in Health Care identifies failure to communicate safety information to patients as a systemic risk across medical device management.
Failure to notify patients of recalls
When the TGA or a manufacturer issues a recall or hazard alert, the prescribing clinician and the health service both carry responsibility for telling affected patients. In practice, many patients learned about MiniMed recalls through media reports — not from their doctor. A clinician who knew about a recall and did not notify their patient may have breached their duty of care.
Dismissing reported symptoms
Several patients and carers reported unexplained glucose fluctuations to their clinical team, only to receive reassurance that the pump was “fine.” Clinicians who attributed these reports to diet or user error — without investigating whether the device itself was malfunctioning — missed a critical opportunity to prevent harm.
Failure to replace or withdraw the device
Once a recall applies to a specific pump model, the standard response is to replace the device or move the patient to an alternative therapy. Clinicians who allowed patients to continue using a recalled device — without documenting a clear clinical reason and obtaining informed consent — may have exposed those patients to foreseeable harm.
Inadequate monitoring after a known problem
Even where a pump problem was identified, some patients received no increase in monitoring. A patient whose pump had already malfunctioned once needed closer follow-up — not a return to routine review intervals. Failing to increase monitoring after a known device event is a recognisable pattern of substandard care.
Failure to provide adequate training
Insulin pumps are complex. Patients must understand how to respond to alarms, how to switch to manual injections if the pump fails, and what symptoms should prompt them to seek urgent help. Clinicians who prescribed a MiniMed pump without providing this training — or without confirming the patient understood it — created a foreseeable risk of harm.
Reported glucose fluctuations triggered a device check, not just dietary advice.
A recalled pump was replaced or the patient moved to an alternative therapy.
Training covered what to do if the pump failed or behaved unexpectedly.
Follow-up appointments increased after any known device event.
Repeated reports of unexplained glucose swings were attributed to user error.
The recalled pump remained in use for weeks or months after the alert.
Training was minimal — the patient did not know how to respond to a failure.
Monitoring continued at routine intervals despite a known malfunction.
Why this matters legally
Every clinician who treats a patient owes that patient a duty of care — a legal obligation to provide treatment that meets the standard of a competent practitioner in the same field. This duty does not disappear because a device manufacturer caused the underlying problem. A prescribing doctor, an endocrinologist, a diabetes nurse, or a hospital all carry their own obligations to the patient.
Not every pump malfunction gives rise to a legal claim. Devices can fail in ways that no clinician could have predicted or prevented. The legal question is narrower: did the clinician do what a competent clinician in their position would have done? If a recall existed and the clinician did not act on it, that gap may constitute a breach. If a patient reported symptoms and the clinician dismissed them without investigation, that too may be a breach.
Importantly, the harm must flow from the breach — not just from the device failure itself. A patient who suffered a hypoglycaemic seizure because their pump over-delivered insulin may have a claim against the manufacturer. But if their clinician also knew about the recall and failed to act, the clinician’s inaction may have contributed to the harm independently.
For a broader explanation of how medical negligence law works in NSW, Reframe Legal — Medical Negligence provides a plain-English overview.
A pump malfunction that occurred despite the clinician following all recall protocols, providing full training, and monitoring appropriately — device failures can happen even with excellent clinical care
A clinician who knew about a TGA recall, did not notify the patient, and the patient then suffered a serious hypoglycaemic event directly linked to the recalled device’s failure mode
This is a general educational framework only. Each case is assessed on its individual facts.
When a MiniMed pump failure may amount to medical negligence
The NSW Civil Liability Act 2002 sets out the legal framework for negligence claims in this state. In plain terms, it requires a court to ask whether a reasonable clinician in the same position would have acted differently — and whether acting differently would have prevented the harm.
Several specific scenarios may give rise to a claim in the MiniMed context.
If your clinician knew about a recall and did not tell you — and you continued using the recalled device and suffered harm — the failure to notify may constitute a breach of the duty to provide safe care.
If you reported repeated unexplained glucose swings and your clinician attributed them to your behaviour without investigating the device — and you later suffered a serious hypoglycaemic or hyperglycaemic event — the failure to investigate may be the breach that caused your harm.
If your clinician allowed you to continue using a recalled pump without explaining the risks, without offering an alternative, and without documenting your informed agreement to continue — that failure to obtain informed consent may itself be a separate legal issue.
If you were not trained in how to respond to a pump failure — and you did not switch to manual injections when the pump malfunctioned because nobody told you how — the gap in training may have directly caused or worsened your harm.
When harm becomes long-term or permanent
A single serious hypoglycaemic event can cause permanent brain damage. Prolonged hyperglycaemia — high blood sugar left untreated — damages kidneys, eyes, nerves, and blood vessels over time. For many MiniMed patients, the harm did not stop when the pump was replaced.
Physical consequences
Severe hypoglycaemia can cause cognitive impairment, memory loss, and in the most serious cases, death. Repeated episodes — even moderate ones — accumulate neurological damage. Some patients developed hypoglycaemia unawareness, a condition where the body stops producing warning symptoms before blood sugar drops to a dangerous level.
Prolonged hyperglycaemia accelerates diabetic complications. Patients who spent weeks or months with poorly controlled blood sugar — because their pump was under-delivering without anyone noticing — may have suffered kidney damage, retinal damage, or peripheral neuropathy that would not have developed with proper device management.
Psychological consequences
Living through a hypoglycaemic seizure is traumatic. Many patients develop significant anxiety about their blood sugar levels after a serious event. Some develop a fear of hypoglycaemia so severe that they deliberately run their blood sugar higher than recommended — which itself causes long-term harm. Carers and family members who witnessed a serious event often carry their own psychological burden.
Financial consequences
Hospitalisation, specialist review, additional monitoring equipment, and lost income during recovery all carry real financial costs. For patients who suffered permanent impairment, the financial impact extends across a lifetime — reduced earning capacity, ongoing care needs, and the cost of managing accelerated diabetic complications.
What compensation can cover in MiniMed pump cases
NSW compensation law allows a successful claimant to recover for pain and suffering, lost income, past and future medical expenses, and the cost of care provided by family members. In cases involving permanent impairment, courts also consider future earning capacity and the lifetime cost of managing ongoing health needs.
| Level of harm | Typical compensation range |
|---|---|
| Moderate injury | $50,000–$150,000 |
| Serious injury | $150,000–$500,000 |
| Severe / life-changing injury | $500,000+ |
Each case is assessed on its own facts. These figures are general ranges only. The severity of the hypoglycaemic event, the degree of permanent impairment, and the strength of the link between the clinical failure and the harm all affect the outcome.
Time limits apply in NSW. Generally, a person has three years from the date they knew — or ought reasonably to have known — that they suffered harm as a result of negligence. For children, different rules apply. Acting sooner rather than later preserves evidence and options.
Bringing it together — do the pieces fit?
You may be reading this because something went wrong and you are not sure whether anyone is responsible. That uncertainty is normal. These situations are genuinely complex — a device manufacturer, a prescribing doctor, a hospital, and a diabetes nurse may all have played a role.
Understanding whether the pieces fit requires looking at what your clinical team knew, when they knew it, and what a competent team in their position would have done differently. Reframe Legal — How Medical Negligence Claims Work in NSW explains that process in plain terms.
You don’t need certainty to understand your position
Many people who experienced a MiniMed pump failure spent months — sometimes years — wondering whether what happened to them was avoidable. Self-doubt is common. Patients often assume that because their doctor seemed competent and caring, nothing could have gone wrong legally. Those two things are not mutually exclusive.
A clinician can be a good person and still have fallen below the legal standard of care. Recalls get missed. Symptoms get misattributed. Training gets skipped. None of these failures require bad intent — they require only that the care fell short of what a competent practitioner would have done.
Legal clarity does not come from certainty about what happened. It comes from examining the facts — the clinical records, the recall timelines, the documented communications — against the standard of care. That examination is what a medical negligence lawyer does.
If consent was not properly obtained before you continued using a recalled device, that issue carries its own legal weight. Reframe Legal — Informed Consent and Medical Negligence explains what informed consent requires and when its absence becomes legally significant.
If you want to understand whether your clinician’s conduct meets the standards set by their registration body, AHPRA — Australian Health Practitioner Regulation Agency sets out the professional standards that apply to registered health practitioners in Australia.
About the lawyer behind this article
Dr Rosemary Listing is an Australian lawyer with a PhD focused on medical negligence. Her academic and legal work examines how clinical systems fail patients — and what the law requires when they do.
Insulin pump cases sit at the intersection of device liability and clinical responsibility. Dr Listing has examined cases where patients suffered serious harm after their clinical team failed to act on known device alerts — and where the harm was preventable with timely, competent action.
In MiniMed pump cases, the harm rarely comes from the malfunction alone. It comes from the gap between what the clinical team knew and what they did with that knowledge. That gap is where legal accountability lives.
People who seek legal clarity in these situations are not looking to blame anyone. Most want to understand whether what happened to them — or to someone they love — was avoidable, and whether the law recognises that.
Dr Listing’s role is to assess the facts against the standard of care — carefully, honestly, and without overpromising. Her focus is on whether the care provided met the legal threshold, not on whether the outcome was unfortunate.
This article is general legal information only. It does not constitute legal advice. Each person’s circumstances are different. The law discussed applies to New South Wales, Australia. Time limits apply to legal claims.